Molecular homology and difference between spontaneous canine mammary cancer and human breast cancer

Cancer Research

Volumn 74, Issue 18, 2014, Pages 5045-5056

  Liu, Deli ^a   Xiong, Huan ^a   Ellis, Angela E ^b   Northrup, Nicole C ^b   Rodriguez, Carlos O ^c   O'Regan, Ruth M ^d   Dalton, Stephen ^a   Zhao, Shaying ^a  

^a University of Georgia   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ANIMAL; BREAST TUMOR; DISEASE MODEL; DOG; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; NUCLEIC ACID HYBRIDIZATION; PATHOLOGY;

ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, ANIMAL; NUCLEIC ACID HYBRIDIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84907529004     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0392     Document Type: Article

References (50)

1. Meuten DJ. Tumors in domestic animals. 4th ed. Ames, Iowa: Iowa State University Press; 2002.
2. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008;8:147-56.
3. Rowell JL, McCarthy DO, Alvarez CE. Dog models of naturally occurring cancer. Trends Mol Med 2011;17:380-8.
4. Gordon I, Paoloni M, Mazcko C, Khanna C. TheComparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med 2009;6:e1000161.
5. Tang J, Le S, Sun L, Yan X, Zhang M, Macleod J, et al. Copy number abnormalities in sporadic canine colorectal cancers. Genome Res 2010;20:341-50.
6. Youmans L, Taylor C, Shin E, Harrell A, Ellis AE, Seguin B, et al. Frequent alteration of the tumor suppressor gene APC in sporadic canine colorectal tumors. PLoS ONE 2012;7:e50813.
7. Tang J, Li Y, Lyon K, Camps J, Dalton S, Ried T, et al. Cancer driverpassenger distinction via sporadic human and dog cancer comparison: a proof-of-principle study with colorectal cancer. Oncogene 2014;33:814-22.
8. Parker HG, Shearin AL, Ostrander EA. Man's best friend becomes biology's best in show: genome analyses in the domestic dog. Annu Rev Genet 2010;44:309-36.
9. Nasir L, Devlin P, McKevitt T, Rutteman G, Argyle DJ. Telomere lengths and telomerase activity in dog tissues: a potential model system to study human telomere and telomerase biology. Neoplasia 2001;3:351-9.
10. Rangarajan A, Weinberg RA. Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 2003;3:952-9.
11. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005;438:803-19.
12. Ji X, Zhao S. DA and Xiao-two giant and composite LTR-retrotransposon-like elements identified in the human genome. Genomics 2008;91:249-58.
13. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
14. Beck J, Hennecke S, Bornemann-Kolatzki K, Urnovitz HB, Neumann S, Strobel P, et al. Genome aberrations in canine mammary carcinomas and their detection in cell-free plasma DNA. PLoS ONE 2013;8:e75485.
15. Klopfleisch R, Lenze D, Hummel M, Gruber AD. Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles. BMC Cancer 2010;10:618.
16. Paw Owski KM, Maciejewski H, Dolka I, Mol JA, Motyl T, Krol M. Gene expression profiles in canine mammary carcinomas of various grades of malignancy. BMC Vet Res 2013;9:78.
17. Rao NA, Van Wolferen ME, Gracanin A, Bhatti SF, Krol M, Holstege FC, et al. Gene expression profiles of progestin-induced canine mammary hyperplasia and spontaneous mammary tumors. J Physiol Pharmacol 2009;60 Suppl 1:73-84.
18. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486:400-4.
19. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012;486:405-9.
20. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus codingsequences ofhumanbreastandcolorectalcancers. Science 2006;314:268-74.
21. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 2012;486:346-52.
22. Naylor TL, Greshock J, Wang Y, Colligon T, Yu QC, Clemmer V, et al. High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res 2005;7:R1186-98.
23. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
24. Sleeckx N, De Rooster H, Veldhuis Kroeze EJ, Van Ginneken C, Van Brantegem L. Canine mammary tumours, an overview. Reprod Domest Anim 2011;46:1112-31.
25. Adriance MC, Inman JL, Petersen OW, Bissell MJ. Myoepithelial cells: good fences make good neighbors. Breast Cancer Res 2005;7:190-7.
26. Gudjonsson T, Adriance MC, Sternlicht MD, Petersen OW, Bissell MJ. Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. J Mammary Gland Biol Neoplasia 2005;10:261-72.
27. Lakhani SR, O'Hare MJ. The mammary myoepithelial cell-Cinderella or ugly sister? Breast Cancer Res 2001;3:1-4.
28. Moumen M, Chiche A, Cagnet S, Petit V, Raymond K, Faraldo MM, et al. The mammary myoepithelial cell. Int J Dev Biol 2011;55:763-71.
29. Polyak K, Hu M. Do myoepithelial cells hold the key for breast tumor progression? J Mammary Gland Biol Neoplasia 2005;10:231-47.
30. Sopel M. The myoepithelial cell: its role in normal mammary glands and breast cancer. Folia Morphol 2010;69:1-14.
31. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008;13:394-406.
32. Tan PH, Ellis IO. Myoepithelial and epithelial-myoepithelial, mesenchymal and fibroepithelial breast lesions: updates from the WHO Classification of Tumours of the Breast 2012. J Clin Pathol 2013;66:465-70.
33. Hayes MM. Adenomyoepithelioma of the breast: a review stressing its propensity for malignant transformation. J Clin Pathol 2011;64:477-84.
34. Goldschmidt M, Pena L, Rasotto R, Zappulli V. Classification and grading of canine mammary tumors. Vet Pathol 2011;48:117-31.
35. Bryson JL, Griffith AV, Hughes B III, Saito F, Takahama Y, Richie ER, et al. Cell-autonomous defects in thymic epithelial cells disrupt endothelial-perivascular cell interactions in the mouse thymus. PLoS ONE 2013;8:e65196.
36. Volik S, Zhao S, Chin K, Brebner JH, Herndon DR, Tao Q, et al. Endsequence profiling: sequence-based analysis of aberrant genomes. Proc Natl Acad Sci U S A 2003;100:7696-701.
37. Lademann U, Kallunki T, Jaattela M. A20 zinc finger protein inhibits TNF-induced apoptosis and stress response early in the signaling cascades and independently of binding to TRAF2 or 14-3-3 proteins. Cell Death Differ 2001;8:265-72.
38. Sauer J, Sigurskjold BW, Christensen U, Frandsen TP, Mirgorodskaya E, Harrison M, et al. Glucoamylase: structure/function relationships, and protein engineering. Biochim Biophys Acta 2000;1543:275-93.
39. Costello M, Pugh TJ, Fennell TJ, Stewart C, Lichtenstein L, Meldrim JC, et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res 2013;41:e67.
40. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2012;45:136-44.
41. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400.
42. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011;11:481-92.
43. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12-27.
44. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5-23.
45. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. Nat Rev Cancer 2004;4:177-83.
46. Samuels Y, Wang ZH, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene inhumancancers. Science 2004;304:554.
47. Wendt MK, Taylor MA, Schiemann BJ, Schiemann WP. Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell 2011;22:2423-35.
48. Gordon V, Banerji S. Molecular pathways: PI3K pathway targets in triple-negative breast cancers. Clin Cancer Res 2013;19:3738-44.
49. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010;7:403-17.
50. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009;15:907-13.